"The FDA has said that phase 2 data suggest the drug could represent a new therapy option for men whose cancer has progressed despite chemotherapy, and treatment with androgen receptor therapy such as Pfizer/Astellas’ Xtandi (enzalutamide), or Johnson & Johnson’s Zytiga (abiraterone)."
Thanks for the post. I'll be looking for the TRITON announcement. I think as promising as these drugs are, as a monotherapy, they have limited effectiveness which is measured in months (median). It would be more interesting to see them combined with another agent, such as PD-1 (there are some clinical trials ongoing). There's already proof of Zytiga plus Olaparib combo (from your link):
I was offered the above combo by one MO, but decided not to opt for it because I feel the benefits maybe limited, and having spoken to a few Onc's, the new agents (PD/PDL-1) may hold a better promise.
recombo/BRCA group here are definitely benefiting from large crossover works getting done in Breast and Ovarian.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.